Introduction
Periodontal disease is a chronic microbial infection characterized by the inflammation of supportive tissues and alveolar bone loss. Particularly in chronic periodontitis, the presence of local irritants is compatible with the severity of the disease. 1 Although bacteria are essential in the onset and maintenance of periodontitis, susceptibility and disease progression are determined by a complex interaction driven by the modulation of an immune-inflammatory host response. 2, 3 Locally, bacterial lipopolysaccharides induce inflammatory cells to release pro-inflammatory mediators that seem to act in the destruction of periodontal tissues. 3 The presence of inflammatory cells and lymphocytes infiltration, chemotactic factors involved in recruiting these cells and cytokines involved in the pathogenesis and progression of the periodontal disease. 4
The activation of a local immune response by T helper cells would determine the stability or progression of the periodontal disease. Th1 lymphocytes are characterized by the secretion of cytokines involved in eradicating intracellular pathogens, whereas Th2 cells are responsible for secreting cytokines involved in eliminating extracellular micro-organisms. 5 Also, Th17 and T regulatory (Treg) cells are involved in disease progression. Th17 subset presents pro-inflammatory and pro-resorptive activities, especially for secretion of IL-17 and RANKL, both involved in the differentiation and activation of osteoclasts. On the other hand, Treg cells subset displays suppressor functions producing IL-10 and transforming growth factors (TGF-β 1 ). 6, 7 In this context, IL-10 seems to have a modulatory role on inflamed and progressive sites.
Host modulatory effects of specific cytokines such as IL-10, IL-13, OPG and TGF-β 1 are responsible for the selective recruitment of different cells, cytokines production and may determine the disease progression. 8 These cytokines associated to host defense have been identified in saliva, 3, 9 blood, 10, 11 gingival crevicular fluid 8, 11 and gingival tissues. 12, 13 Elevated levels of these molecules may be related to periodontal disease condition, allowing identification and controlling patients with periodontal disease. 14 Studies that aim to analyze cytokines host modulatory effect during disease progression seem to be promising in periodontal diagnostic. 15 
Clinical parameters
Clinical examinations and data collections were performed at day -15, baseline and two months after basic periodontal therapy. Figure 1 were also recorded. 18 It was also verified the furcation 
Saliva collection and analysis
The patients were instructed not to drink or eat for at least 60 min before the saliva sample collection.
Non-stimulated whole expectorated saliva was collected (~3 ml) from each subject into sterile tubes, according to the method described by Navazesh 22 
Clinical parameters
For intra-group comparison, before and after treatment, Wilcoxon test or t test was applied. For intergroup comparison, Mann-Whitney test or t test was applied. A significance level of 5% was adopted for all statistical analyses (P<0.05). 
Gingival crevicular fluid proteins

Results
Clinical findings
The subjects' demographic data are displayed in Table 1 . There was a higher prevalence of women and Caucasians in our sample. At baseline, periodontitis and control groups had different mean values of clinical parameters ( Table 1) . After basic periodontal therapy, periodontitis group showed a significant improvement in the clinical parameters (p<0.05).
Significant differences between inflamed and non-
inflamed sites for PD, rCAL and BOP, and between inflamed and control sites for PD and PI (p<0.05) ( therapy, 17% of total sites showed progressive clinical attachment loss (p<0.05).
Comparisons of clinical measurements between
-15 days and baseline, without any interventional therapy, showed difference in PD (5.6±0.85 and 5.9±1.30, respectively) in inflamed sites, but not significant (p=0.37). For non-inflamed sites (2.7±0.6 and 2.5±0.9, respectively), difference was also not significant (p=0.39).
Salivary proteins
In the baseline, higher expression of RANK-L in periodontitis group 2.99 pg/mL in comparison to control group 1.2 pg/mL (p=0.0313) was observed. OPG protein expression was higher in periodontitis group before therapy. After 2 months, a 40% reduction was observed (p=0.0002).
Gingival crevicular fluid proteins
Eighty-one samples were included for the gingival crevicular fluid analyses. IL-10, VEGF and MMP-8 were detected in gingival crevicular fluid collected at baseline, 15 days and 2 months ( Figure 2 ). Our data showed a higher total amount of VEGF in inflamed sites in comparison to non-inflamed sites at all times.
There were no differences between baseline and 2
Control (n = 9)
Periodontitis (n = 18) *P Value months in all sites.
The total amount of IL-10 was higher in inflamed sites in comparison to non-inflamed sites at all times (p<0.05). Also, non-inflamed sites showed higher amounts of IL-10 in comparison to control sites at all times (p<0.05).
The total amount of MMP-8 had a reduction 15 days after periodontal therapy, but not statistically significant, and the total amount was higher in inflamed sites after two months (p<0.05). Also, it was higher in control sites in comparison to non-inflamed sites after 15 days (p<0.05). (Figure 3 ).
Discussion
In the present study, we monitored inflammation and progressive periodontal sites to investigate potential differences in the molecular profile of gingival crevicular fluid and gingival biopsies from inflamed and non-inflamed sites. Groups and sites were categorized in order to express significant clinical differences measured by periodontal parameters (PD a rCAL) and inflammation (BOP). Additionally, early changes in the clinical attachment levels were used to investigate the role of inflammatory markers in disease modulation.
Samples were collected at baseline, 15 days and 2 months after basic periodontal therapy. As expected, our data showed significant difference in clinical parameters between periodontitis group and control group at baseline. After periodontal therapy, data showed significant improvements on clinical parameters in periodontitis group. It was observed reduction in PD (0.7 mm ±0.4), BOP (37.1%±5.0), PI (27.2%±7.3), and rCAL gain (0.9 mm ±0.5). These results confirm the short-term beneficial effect of the therapy and are in accordance with previous data that showed better clinical conditions after full mouth disinfection 24, 25 or scaling and root planning over a 3to 4-week period. 26, 27 Inflamed sites showed higher amount of IL-10 (0.29 pg ±0.09) in comparison to control sites (0.21 pg ±0.08) before treatment (p<0.05). Furthermore, Periodontal disease activity is accepted as bone and attachment loss 32 related to variations in inflammatory cells, migration of monocytes/macrophage 33 and has been associated to inflammatory biomarkers. 7, 34, 35 Our results found that 17% of total sites could be classified as progressive, according to the tolerance method. 20, 21, 36 However, we did not find differences Regarding VEGF, we found significant difference between inflamed sites and control sites at all times.
This result is subject to bias given gingival tissue samples collected from sites that received periodontal therapy. Besides, the presence of VEGF in gingival fluid of healthy patients may reflect sub-clinical levels of inflammation, healing following bacterial assault or physiological angiogenesis in periodontal tissues. 40 Despite having some sites with periodontal disease progression, our site-specific analysis also showed considerable levels of anti-inflammatory markers, possibly reducing risk for more attachment loss.
In conclusion, in spite of data analysis limitations and the short follow-up period to appreciate major disease breakdown, this preliminary study stressed out that progressive disease activity is a possible occurrence even after basic periodontal therapy, but is limited to a small percentage of sites. Also, periodontal treatment reduces elevated inflammation markers of inflamed sites from disease patients to levels of those observed in healthy subjects, but these levels could not be sustained in case of residual periodontal Clinical attachment loss and molecular profile of inflamed sites before treatment J Appl Oral Sci. 2019;27:e20180671 9/10 pockets. However, as elevated gene and protein antiinflammatory marker levels in inflamed sites prior treatment could suggest its modulatory role, it does not seem to discriminate future progressive sites.
Predictors of future attachment loss are still a challenge in periodontal diagnosis.
